Blood RNA may reveal who responds to heart failure treatment
NCT ID NCT03345446
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at tiny RNA molecules in the blood of 200 people hospitalized with acute congestive heart failure. Researchers want to see if these RNA levels change as patients receive decongestive therapy and if they can help predict who will respond well to treatment. The goal is to better understand heart failure and find new markers to guide care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CONGESTIVE HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could continuing a common heart drug before surgery save lives?
- Could a natural chemical be the key to safer heart failure treatment?
- Can a Breathing-Synchronized pacemaker boost heart function after bypass?
- Can 3D heart scans outperform standard ultrasound in predicting risk?
- Iron infusions put to the test for heart failure stamina
- Leg workouts may unlock a hidden cause of exercise intolerance in common heart failure